NeoStem, Inc. CEO's Letter to Shareholders
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
NEW YORK, May 9, 2013 (GLOBE NEWSWIRE) --
Dear Shareholders,
We at NeoStem, Inc. (NYSE MKT:NBS) believe that cell therapy has the potential to radically change the face of how diseases are treated, leading to longer and, more importantly, higher quality lives. NeoStem is proud of its role at the forefront of this paradigm shift underway in medicine toward cell therapy – a shift away from treating disease with drugs and toward treating disease with our own cells; a shift away from treating symptoms and toward cures for the illnesses that cause the most suffering; a shift away from chemical drug development and toward looking inside ourselves to understand and then amplify our body's natural repair mechanisms.
Help employers find you! Check out all the jobs and post your resume.
NEW YORK, May 9, 2013 (GLOBE NEWSWIRE) --
Dear Shareholders,
We at NeoStem, Inc. (NYSE MKT:NBS) believe that cell therapy has the potential to radically change the face of how diseases are treated, leading to longer and, more importantly, higher quality lives. NeoStem is proud of its role at the forefront of this paradigm shift underway in medicine toward cell therapy – a shift away from treating disease with drugs and toward treating disease with our own cells; a shift away from treating symptoms and toward cures for the illnesses that cause the most suffering; a shift away from chemical drug development and toward looking inside ourselves to understand and then amplify our body's natural repair mechanisms.
Help employers find you! Check out all the jobs and post your resume.